Abstract
Carbonic anhydrase IX (CA IX) is an extracellular transmembrane homodimeric zinc metalloenzyme that has been validated as a prognostic marker and therapeutic target for several types of aggressive cancers. CA IX shares a close homology with other CA isoforms, making the design of CA IX isoform selective inhibitors challenging. In this paper, we describe the development of a new class of CA IX inhibitors that comprise a sulfamate as the zinc binding group, a variable linker, and a carbohydrate "tail" moiety. Seven compounds inhibited CA IX with low nM K i values of 1-2 nM and also exhibited permeability profiles to preferentially target the binding of extracellular CA IX over cytosolic CAs. The crystal structures of two of these compounds in complex with a CA IX-mimic (a variant of CA II, with active site residues that mimic CA IX) and one compound in complex with CA II have been determined to 1.7 Å resolution or better and demonstrate a selective mechanism of binding between the hydrophilic and hydrophobic pockets of CA IX versus CA II. These compounds present promising candidates for anti-CA IX drugs and the treatment for several aggressive cancer types.
Cite
CITATION STYLE
Moeker, J., Mahon, B. P., Bornaghi, L. F., Vullo, D., Supuran, C. T., McKenna, R., & Poulsen, S. A. (2014). Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates. Journal of Medicinal Chemistry, 57(20), 8635–8645. https://doi.org/10.1021/jm5012935
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.